[Remote] Senior Division Manager (Southeast Region) at Arcellx

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates must possess a Bachelor's degree, with an advanced degree being preferred. A minimum of 10 years of biotech/pharma sales experience is required, including at least 3 years in a sales leadership role. Prior cross-functional experience and a proven track record in hematology/oncology and/or cell therapy markets are highly valued. Strong inspirational leadership, clear communication, and advanced coaching and team development skills are essential, as is an innovative and strategic mindset with experience in building, coaching, and implementing actionable account plans. The role requires at least 50% travel.

Responsibilities

The Senior Division Manager will be responsible for attracting, retaining, and developing a high-performing divisional field sales team, onboarding and training them to exceed launch expectations, and leading them to meet and exceed sales and performance goals. This includes analyzing market trends and competitive activity to inform strategy, developing and implementing divisional sales plans aligned with company objectives, and supporting the team in executing strategic territory and account plans. The manager will also proactively engage with key customers to build relationships and advocacy, collaborate with partner organizations and key stakeholders, and lead commercial activities at scientific meetings, ensuring compliance with all regulatory and legal requirements.

Skills

Sales Strategy

Team Leadership

CAR T

Biotechnology

Oncology

Multiple Myeloma

Sales Management

Launch Strategy

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free